Revolution Medicines, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Brookline Capital Markets initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a buy rating and a $318 price target. The stock is up 367% over the past year. Brookline estimates revenue growing from $151M in 2026 to $59.5B in 2033, with positive cash flow expected in 2027. The company recently launched Rasonque for pancreatic cancer, with FDA approval based on improved survival rates.
Revolution Medicines (RVMD) received FDA Breakthrough Therapy Designation for its cancer treatment, boosting its profile. The stock has surged 152.92% year-to-date, with analysts valuing it at $251.21, above its current $199.86. The company's pipeline includes eight Phase III trials, with potential long-term revenue growth if successful.
Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning RVMD (Revolution Medicines, Inc.). Coverage has skewed bullish: 13 bullish, 1 neutral, and 1 bearish.
Recent RVMD coverage spans financial news, technology and regulation.
In the last 30 days, RVMD insiders filed 47 SEC Form 4 transactions — no purchases and 47 sales ($45.9M). The most active reporter was Kim Lorence H. with 14 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst initiation and high price target suggest upside potential.
The designation validates the clinical potential of the RAS‑ON pipeline and could accelerate regulatory timelines, supporting a higher valuation.
Potential acceleration of drug approval could boost RVMD valuation.
Significant insider sell may signal negative sentiment; potential short‑term pressure on RVMD.
Analyst initiation may lift sentiment and support price appreciation.
AlphAI scores every news story that mentions RVMD with an AI model for sentiment and relevance, and aggregates insider trades from Revolution Medicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Brookline Capital Markets initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a buy rating and a $318 price target. The stock is up 367% over the past year. Brookline estimates revenue growing from $151M in 2026 to $59.5B in 2033, with positive cash flow expected in 2027. The company recently launched Rasonque for pancreatic cancer, with FDA approval based on improved survival rates.
2 min readRevolution Medicines (RVMD) received FDA Breakthrough Therapy Designation for its cancer treatment, boosting its profile. The stock has surged 152.92% year-to-date, with analysts valuing it at $251.21, above its current $199.86. The company's pipeline includes eight Phase III trials, with potential long-term revenue growth if successful.
2 min readRevolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.
3 min readANDERSON ELIZABETH M sold 10,143 shares of Revolution Medicines, Inc. (RVMD) at an average of $193.04 ($191.85–$195.15, $1.96M total) across 5 trades on 2026-09-22 under a Rule 10b5-1 trading plan.
1 min readGoldman Sachs initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and $267 price target, citing its oncology platform. The stock has surged 338% in the past year, trading at $190.74. Revolution's lead drug, Rasonque, was recently approved for pancreatic cancer, with trials ongoing for other indications. Analysts have raised price targets and earnings estimates following the approval.
2 min readGoldman Sachs resumed coverage of Revolution Medicines (RVMD) with a Buy rating and $267 price target. The company, trading at a high P/S ratio, is unprofitable but has a strong balance sheet. Insiders have sold shares, while some gurus have increased holdings. RVMD's GF Score is 25/100, indicating financial challenges.
2 min readAnalysts updated ratings and price targets for several companies. Citi downgraded Dropbox to sell, reducing its target to $29. Arete Research downgraded Etsy to neutral, lowering its target to $81. Goldman Sachs initiated coverage of Madrigal and Revolution with buy ratings and targets of $704 and $267, respectively. Meta was upgraded to buy by President Capital, which raised its target to $897. Paychex was upgraded to neutral by JP Morgan, which raised its target to $115.
2 min readRevolution Medicines' Chief Global Commercialization Officer Anthony Mancini sold 1,764 shares of the company's stock on September 18, 2026, totaling $347,402. The sale was part of a pre-arranged trading plan. RVMD shares have surged 334% over the past year, trading at $192.86. The company recently received FDA approval for its drug Rasonque, leading to multiple analyst price target increases.
1 min readRevolution Medicines director Elizabeth Anderson filed a Rule 144 notice to sell 15,080 shares, valued at $2.91M, over three months. The shares will be acquired via cash exercise of stock options and sold via Morgan Stanley Smith Barney LLC, with a stated sale date of September 22, 2026, on NASDAQ.
1 min readBofA Securities named Revolution Medicines (RVMD) its top biotech pick, citing strong sector performance and the company's recent drug approval. RVMD shares have a Buy rating and a $265 price target, up from $225. The company has a $3.9B cash position and a strong pipeline, with multiple clinical programs underway. Other analysts have also raised their price targets for RVMD.
2 min read
